Equillium's Itolizumab Shows Durable Clinical Response In GvHD Patients

Equillium Inc EQ announced two oral presentations on itolizumab at the Annual Meeting of the European Society for Blood and Marrow Transplantation. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!